The 29th JFCR－ISCC
December 10-11, 2025
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan
December 10
12:00-12:30
Committee meeting
Opening Remark
12:50-13:00
Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)
Opening remark
Antibody therapeutics: Targeting to functional design
13:00-13:30
Yosuke Yoshida (Daiichi Sankyo Co., Ltd., Tokyo)
Clinical development of R-DXd, a novel CDH6-targeting DXd-ADC
13:30-14:00
Hiroki Hayashi (Chugai Pharmaceutical Co., Ltd., Kanagawa)
ROSE12, A Novel ATP-dependent FcγRs affinity-enhanced anti-CTLA-4 switch antibody for tumour-selective enhancement of anti-tumour immunity
14:00-14:10
Discussion
Meet-the-Expert 1
14:10-14:50
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH, Boston, MA, USA)
Combination strategies to increase the efficacy of KRAS inhibition
14:50-15:00
Discussion
15:00-15:20
Coffee Break
Targeting RAS-driven cancers
15:20-15:50
Hiromichi Ebi (Aichi Cancer Center Research Institute, Aichi)
KRAS-mutant cancers: Current landscape and emerging therapies
15:50-16:30
TBD
16:30-17:00
Pankaj Punia (Astellas Pharma Oncology Development, Addlestone, UK)
Development spotlight: Advancing KRAS-targeted therapies through ASP5834 and ASP3082
17:00-17:10
Discussion
Poster Flash talk
17:10-17:55
Poster viewing and networking
17:55-19:10
December 11
Mapping cancer at single-cell resolution
9:00-9:40
Ignacio Vazquez-Garcia (MGH, Harvard Medical School, Boston, MA, USA)
Tracing cancer dynamics at single-cell resolution
9:40-10:20
Sydney M. Shaffer (University of Pennsylvania, Philadelphia PA, USA)
Tracking and targeting dynamic cell states in therapy resistance
10:20-10:50
Ayako Suzuki (The University of Tokyo, Tokyo)
Elucidating aberrant tumor cell and microenvironment status in spatial and single-cell omics analysis
10:50-11:00
Discussion
11:00-11:20
Coffee Break
Meet-the-Expert 2
11:20-12:00
Liron Bar-Peled (MGH Cancer Institute, Harvard Medical School, Boston, MA, USA)
An ‘Omics approach to drug discovery
12:00-12:10
Discussion
Luncheon Seminar (Supported by Nippon Kayaku )
12:20-13:10
Misako Nagasaka (University of California Irvine School of Medicine , Irvine, CA, USA)
Updates in ROS1-positive NSCLC: Advances in ROS1 inhibitors and strategies against resistance
13:10-13:20
Break
Groundbreaking advances in cancer immunotherapy
13:20-13:50
Yosuke Togashi (Okayama University, Okayama)
Tumor-derived mitochondrial “Hijack” in the tumor microenvironment
13:50-14:20
Keisuke Watanabe (NCC, Tokyo)
Engineering CARs for T-cell malignances and solid tumors
14:20-15:00
Taha Merghoub (Weill Cornell Medicine, New York, NY, USA)
TBD
15:00-15:10
Discussion
15:10-15:30
Coffee Break
AI & Quantum technologies driven drug development
15:30-16:00
Kentaro Yamamoto (Quantinuum K.K., Tokyo)
Quantum computing: pushing the boundary of computational chemistry
16:00-16:30
Reiji Teramoto (Chugai Pharmaceutical Co., Ltd., Kanagawa)
Harnessing the power of ML/AI technologies in antibody drug discovery
16:30-16:40
Discussion
Closing Remark
16:40-16:50
Closing remark